AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34241691
Drug: Non-TNF biologics
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-TNF biologics
Trial: 33142537
Drug: 30 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/kg Mn
Trial: 33142537
Drug: 20 and
RxNorm normalized name: zinc pyrithione 20 MG/ML [Free and Clear]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 and 30 mg/kg Mn and 5 × 10^9 CFU/kg BS
Trial: 35320424
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen therapy
Trial: 36544645
Drug: 0.1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg/kg remimazolam tosylate
Trial: 36544645
Drug: 0.15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15 mg/kg remimazolam tosylate
Trial: 36544645
Drug: 0.2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/kg remimazolam tosylate
Trial: 37728142
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (TAU) only
Trial: 34090464
Drug: N-acetyl cysteine
RxNorm normalized name: N-Acetyl Cysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetyl cysteine (100 mg/kg IV, 3 doses: 2 intraoperative and 1 postoperative)
Trial: 36131349
Drug: Outpatient treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient treatment
Trial: 35201518
Drug: Inflawell® syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inflawell® syrup (Boswellia extract formulation enriched for boswellic acids)
Trial: 38285446
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine
Trial: 34261044
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT)
Trial: 38419049
Drug: Assertive Community
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assertive Community Treatment (ACT)
Trial: 36472389
Drug: Whole-brain radiation
RxNorm normalized name: pork brain preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-brain radiation therapy (WBRT)
Trial: 35148378
Drug: Best-available therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best-available therapy
Trial: 32318268
Drug: High-dose meropenem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose meropenem
Trial: 32291607
Drug: Thick-needle therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thick-needle therapy (TNT)
Trial: 32291607
Drug: Acupuncture therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture therapy (AT)
Trial: 34959111
Drug: 1 Hz
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 Hz repetitive transcranial magnetic stimulation (rTMS) treatment twice a week
Trial: 32108262
Drug: Juçara group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Juçara group (5 g lyophilized juçara)
Trial: 32108262
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group (5 g of maltodextrin)
Trial: 35599921
Drug: Betaine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betaine (2.5 g·d‐1)
Trial: 37422602
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose albumin (1.5 g/kg at diagnosis and 1 g/kg on day three, infused over six hours)
Trial: 37422602
Drug: Reduced dose
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced dose albumin (0.75 g/kg at diagnosis and 0.5 g/kg 48 hours later, infused over six hours)
Trial: 37422602
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose albumin
Trial: 32358661
Drug: Peptide (Prostrolane®)
RxNorm normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peptide (Prostrolane®) injection
Trial: 38839388
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (control group)
Trial: 39424559
Drug: Cognitive Behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioural Therapy (CBT)
Trial: 33858696
Drug: Stress taper
RxNorm normalized name: caper berry extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stress taper fixation
Trial: 35575751
Drug: Sensor-augmented pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sensor-augmented pump therapy
Trial: 32418846
Drug: Alpha Lipoic
RxNorm normalized name: Alpha Lipoic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha Lipoic Acid (ALA) 1200 mg daily
Trial: 35842566
Drug: EOX plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EOX plus aspirin (150 mg daily)
Trial: 33735709
Drug: Baclofen 30
RxNorm normalized name: Baclofen
DrugBank: Baclofen (DB00181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Baclofen 30 mg/day
Trial: 32027206
Drug: Visual Art
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Visual Art Therapy (VAT)
Trial: 32754150
Drug: Micronutrient powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronutrient powder (MNP) with 5 mg iron daily for 4 months starting at age 7.5 months
Trial: 32754150
Drug: Anemia and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anemia and serum transferrin receptor at time of vaccination
Trial: 38334953
Drug: Aspirin challenge
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin challenge
Trial: 34111810
Drug: Algorithm combining
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Algorithm combining ICD codes and FVIII/FIX activity <0.4 IU/ml
Trial: 36436423
Drug: Neoadjuvant endocrine
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant endocrine therapy (NET)
Trial: 35351037
Drug: Cognitive Behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavior Therapy (CBT), one session per week for 3 to 4 months
Trial: 35763229
Drug: Chemoendocrine therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoendocrine therapy (CET)
Trial: 39656951
Drug: Endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine therapy (ET)
Trial: 33356994
Drug: Insulin infusion
RxNorm normalized name: iLet Insulin Infusion 10-Pack Kit Inset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin infusion at 100% of basal rate
Trial: 33356994
Drug: Insulin infusion
RxNorm normalized name: iLet Insulin Infusion 10-Pack Kit Inset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin infusion at 150% of basal rate
Trial: 33356994
Drug: Insulin infusion
RxNorm normalized name: iLet Insulin Infusion 10-Pack Kit Inset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin infusion rate effect on AUCRd
Trial: 39334129
Drug: Heparin monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin monotherapy
Trial: 36351459
Drug: Bivalirudin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalirudin plus a high-dose infusion for 2-4 hours after PCI
Trial: 35083337
Drug: Exercise training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise training in municipality setting (1 hour, twice weekly for 12 weeks)
Trial: 35083337
Drug: Exercise training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise training in hospital setting (1 hour, twice weekly for 12 weeks)
Trial: 33373480
Drug: brodalumab 210
RxNorm normalized name: BRODALUMAB 210MG/1.5ML INJ 1.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: brodalumab 210 mg Q2W
Trial: 34379363
Drug: Participation in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participation in a randomized trial between two treatment durations
Trial: 32000725
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) with VR exposure based on 360° videos
Trial: 32000725
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) with in vivo exposure
Trial: 32000725
Drug: VR relaxation
RxNorm normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: VR relaxation therapy
Trial: 35526272
Drug: Fixed dosing
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dosing regimen
Trial: 34770193
Drug: OHEMA (Oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OHEMA (Oral Health Education Mobile App)
Trial: 33220215
Drug: Standard oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oral iron therapy
Trial: 32648810
Drug: brexpiprazole 2–4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: brexpiprazole 2–4 mg/day
Trial: 32648810
Drug: brexpiprazole 1–4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: brexpiprazole 1–4 mg/day
Trial: 33713718
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (MWD + CDO)
Trial: 38199593
Drug: Behavior therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavior therapy
Trial: 35184491
Drug: Four doses
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four doses of 20 µg vaccination
Trial: 35184491
Drug: Four doses
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four doses of 60 µg vaccination
Trial: 35184491
Drug: Three doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of 20 µg vaccination
Trial: 34499349
Drug: Acetaminophen 1000
RxNorm normalized name: acetaminophen 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 1000 mg
Trial: 37851095
Drug: Placebo solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution
Trial: 37917218
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy
Trial: 35059864
Drug: Bone-modifying agents
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone-modifying agents (BMA)
Trial: 32331914
Drug: Injectable antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injectable antibiotics (primarily penicillins and cephalosporins)
Trial: 32331914
Drug: Analgesics and
RxNorm normalized name: Analgesics and anesthetics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesics and insulin
Trial: 32331914
Drug: Cost of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cost of prescription and injectable drugs
Trial: 35447934
Drug: Placebo, 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 2 grams daily for 180 days
Trial: 34188114
Drug: Stroke lesions
RxNorm normalized name: scabies lesion lysate (human)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stroke lesions in the right putamen and internal capsules of both hemispheres
Trial: 39453400
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no treatment)
Trial: 39085322
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment
Trial: 33683710
Drug: Midazolam (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (2 mg)
Trial: 37246259
Drug: Live Attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live Attenuated Influenza Vaccine (LAIV)
Trial: 33453140
Drug: Unified Protocol
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP)
Trial: 32234756
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with gemcitabine (Gem)
Trial: 35868334
Drug: Liraglutide (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide (one daily subcutaneous injection uptitrated from 0.6-1.8 mg per day over 3 weeks)
Trial: 35868334
Drug: Colesevelam (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colesevelam (three capsules of 625 mg twice daily)
Trial: 39023393
Drug: Nonoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonoperative treatment
Trial: 36027558
Drug: Chemotherapy (eribulin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (eribulin, vinorelbine, capecitabine, or gemcitabine)
Trial: 38849734
Drug: Ketorolac 30
RxNorm normalized name: ketorolac 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 30 mg
Trial: 38126083
Drug: Cognitive behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behaviour therapy
Trial: 35246470
Drug: upadacitinib 30
RxNorm normalized name: upadacitinib 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: upadacitinib 30 mg
Trial: 32396038
Drug: Pilates program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pilates program (36 weeks, twice weekly)
Trial: 34172505
Drug: Routine care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine care plus phone-based weekly pill refilling and daily medication reminders
Trial: 34551581
Drug: Standard bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard bupivacaine (SB) - 60 ml of 0.25% SB
Trial: 32920957
Drug: Fortasyn Connect
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fortasyn Connect (125 mL once-a-day drink)
Trial: 32947496
Drug: Lactic acid
RxNorm normalized name: Lactic Acid
DrugBank: Lactic acid (DB04398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lactic acid (LA) at doses of 30, 60, or 120 mg/mL
Trial: 32947496
Drug: Placebo (iohexol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (iohexol, 1.5 mL)
Trial: 35041662
Drug: Intensive lifestyle
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive lifestyle intervention (increased physical activity, weight loss target 7% through meal replacements and medication Orlistat)
Trial: 34925513
Drug: Chest-to-chest skin-to-skin
RxNorm normalized name: Kids-Eeze Chest Relief
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chest-to-chest skin-to-skin contact (CC SSC)
Trial: 33186312
Drug: Removal of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Removal of the blocker and actively deflating the cuff before SLMA insertion
Trial: 35089607
Drug: Daratumumab in
RxNorm normalized name: daratumumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daratumumab in combination with pomalidomide and dexamethasone (D‐Pd)
Trial: 39719502
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept (IVT-AFL) 2 mg
Trial: 36207063
Drug: Levetiracetam (LEV)
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levetiracetam (LEV) at 1000-3000 mg
Trial: 33404895
Drug: CHF1535 (beclometasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHF1535 (beclometasone dipropionate 50 μg and formoterol fumarate 6 μg via pMDI)
Trial: 33404895
Drug: CHF1535 (beclometasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHF1535 (beclometasone dipropionate 100 μg and formoterol fumarate 12 μg via pMDI)
Trial: 33404895
Drug: CHF1535 (beclometasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHF1535 (beclometasone dipropionate 200 μg and formoterol fumarate 24 μg via pMDI)
Trial: 33404895
Drug: Free combination
RxNorm normalized name: SUNSCREEN-29 PABA-FREE COMBINATION LOT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Free combination of beclometasone dipropionate and formoterol fumarate
Trial: 34736575
Drug: Oral estradiol
RxNorm normalized name: estradiol Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral estradiol (E2) 1 mg/day plus vaginal progesterone (P4) 45 mg/day for 10 days each month
Trial: 39248270
Drug: Placebo injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injection
Trial: 33745439
Drug: MTX test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTX test (20 mg, 2 × 10 mg capsules)
Trial: 33745439
Drug: MTX reference
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTX reference (20 mg, 2 × 10 mg capsules)
Trial: 32276315
Drug: 0.7 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.7 g/day of supplemental eicosapentaenoic acid (EPA) plus docosahexaenoic acid (DHA)
Trial: 32276315
Drug: 1 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g/day of supplemental eicosapentaenoic acid (EPA) plus docosahexaenoic acid (DHA)
Trial: 32276315
Drug: 0 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 g/day (placebo)
Trial: 33464336
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of ACEIs or ARBs
Trial: 32593173
Drug: 250 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 µg IV Synacthen
Trial: 36442353
Drug: Anti-PD-1/PD-L1 therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-PD-1/PD-L1 therapy
Trial: 33567475
Drug: Active arm
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active arm with rescue medication
Trial: 35583186
Drug: Apixaban 5
RxNorm normalized name: apixaban 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apixaban 5 mg (2.5 mg if impaired renal function or concomitant antiplatelet therapy)
Trial: 35583186
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (vitamin K antagonist or antiplatelet therapy)
Trial: 32698430
Drug: Technological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Technological treatment using SonicHand and Riablo™ systems providing auditory and visual biofeedback
Trial: 37979717
Drug: Therapeutic-dose heparin
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic-dose heparin
Trial: 35099994
Drug: Standard prophylactic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard prophylactic or intermediate-dose heparins
Trial: 34203925
Drug: Fucoidan (3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fucoidan (3.0 g/day from beverages)
Trial: 37220815
Drug: Anti-VEGF therapy
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-VEGF therapy
Trial: 35965109
Drug: 0.11 mg
RxNorm normalized name: camphor 0.11 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.11 mg OC-02 SNS
Trial: 35965109
Drug: 0.55 mg
RxNorm normalized name: coumarin 0.55 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.55 mg OC-02 SNS
Trial: 35965109
Drug: 1.1 mg
RxNorm normalized name: menthol 1.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.1 mg OC-02 SNS
Trial: 33975710
Drug: Ultra-low dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra-low dose imaging protocol (ULDP)
Trial: 38662661
Drug: Treatment-as-usual (Control)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-as-usual (Control)
Trial: 32034019
Drug: Valacyclovir (dose-titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valacyclovir (dose-titrated from 2g to a targeted oral dose of 4g daily)
Trial: 35995640
Drug: Aromatherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatherapy with 40% rose essential oil inhalation for three consecutive nights
Trial: 35995640
Drug: Distilled water
RxNorm normalized name: Distilled Water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Distilled water inhalation as placebo
Trial: 34656144
Drug: High-dose PXT3003
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose PXT3003 (6/0.70/210 mg)
Trial: 34656144
Drug: Low-dose PXT3003
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose PXT3003 (3/0.35/105 mg)
Trial: 35846221
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment arms
Trial: 32249170
Drug: Drug-Coated Balloon
RxNorm normalized name: CATHETER,BALLOON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-Coated Balloon (DCB)
Trial: 33386751
Drug: Low maternal
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low maternal education, poor parents' perception of oral health, non-use of dental services, low frequency of tooth brushing
Trial: 37657522
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion (control)
Trial: 33903855
Drug: Camostat mesilate
RxNorm normalized name: Camostat mesilate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camostat mesilate 200 mg three times daily for 5 days
Trial: 36442895
Drug: Internet-based cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive-behavioral therapy
Trial: 34562501
Drug: Ozone treatment
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozone treatment with no activation (NA)